On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression
No abstract is available for this record.
Bibliographic context
Topics and keywords
psilocybin DepressionClinical TrialTreatment-Resistant DepressionSafety Clinical Trial PsilocybinBlindingDepression (economics)Expectancy theoryAdverse effectMedicinePsychiatryTreatment-resistant depressionClinical trialHallucinogenMajor depressive disorderPsychologyInternal medicineCognitionSocial psychologyEconomicsMacroeconomicsPsychedelics and Drug StudiesChemical synthesis and alkaloidsComplementary and Alternative Medicine Studies
Citation graph
0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.
Indexed papers citing this DOI
Related papers
Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidenceAnnals of Medicine and Surgery · 2026-06-17Efficacy and Safety of Psilocybin-Assisted Therapy for Depression: A Meta-Analysis of Randomised Controlled TrialsOpen Access Indonesian Journal of Medical Reviews · 2026-04-20Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) - Rationale and study design.Neuroscience Applied · 2022-03-06